Phil Alabata, DO
Glaucoma Specialist · Crestview, FLNPI 1770547077
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 30.6% of the total. Reporting peaked in 2022 at $3,747 and has fallen 90.0% since, to $375 in 2025.
Across 85 payments — averaging $78.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$2K
- Carl Zeiss Meditec, Inc.$1K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- AbbVie$428
- Glaukos Corporation$194
- plus $334 from 7 others
What the payments were for
- Travel & lodging$1,54023%
- Food & beverage$2,59739%
- Education$2,51838%
- Gifts$361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 8 | $2,045 |
| Carl Zeiss Meditec, Inc. | 2 | $1,328 |
| Alcon | 12 | $1,266 |
| Johnson & Johnson Surgical Vision, Inc. | 26 | $1,094 |
| AbbVie(2 entities) | 16 | $428 |
| Glaukos Corporation | 9 | $194 |
| Aerie Pharmaceuticals, Inc. | 3 | $96 |
| Bausch & Lomb Americas Inc. | 4 | $77 |
| Omeros Corporation | 1 | $57 |
| Rxsight Inc | 1 | $33 |
| Harrow Eye, LLC | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Thea Pharma Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$3,082
- Tecnis IOL$230
- LenSx$145
- Tecnis Simplicity$134
- LUMERA 700$130
- LUMIGAN$116
- Tecnis Multifocal Family of 1-piece IOLS$110
How this compares
$6,691 in reported general payments places this provider in the 70th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 65 | $38,124 |
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $34,865 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 67 | $22,937 |
| CombiganBrimonidine Tartrate/Timolol | 61 | $21,532 |
| RestasisCyclosporine | 13 | $17,282 |
| Alphagan PBrimonidine Tartrate | 40 | $15,177 |
| Prednisolone Acetate | 267 | $11,686 |
| VyzultaLatanoprostene Bunod | 19 | $10,089 |
| IlevroNepafenac | 23 | $8,677 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $7,970 |
| Brimonidine Tartrate | 303 | $7,446 |
| Latanoprost | 540 | $7,231 |
| Bromfenac Sodium | 45 | $6,045 |
| Cyclosporine | 12 | $6,042 |
| MoxifloxacinMoxifloxacin Hcl | 188 | $5,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $428 | $92,115179 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $96 | $34,86544 claims |
| AlconSimbrinza | $1,266 | $22,93767 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $77 | $10,08919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Crestview
- Analisa ArosemenaMiami Beach$438K
- Steven VoldWinter Garden$413K
- Matthew BrinkPalm Beach Gardens$159K
- David GreenfieldMiami$32K
- Mark WernerDelray Beach$24K
- Dan ArreazaHialeah$9K
- Daniel JewelewiczDelray Beach$9K
- Joah AliancyPort Orange$7K
- Clinton SheetsHudson$7K
- Norman LevyGainesville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.